Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis C
100%
Ribavirin
100%
Peginterferon Alpha2a Plus Ribavirin
100%
Hepatitis C Virus
66%
Adverse Event
66%
Hepatitis C
33%
RNA Virus
33%
Anemia
33%
Depression
33%
Fever
33%
Neutropenia
33%
Dermatitis
33%
Virus RNA
33%
Abdominal Pain
33%
Loss of Appetite
33%
Alpha2a Interferon
33%
Flu Like Syndrome
33%
Thyrotoxicosis
33%
Peginterferon Alpha
33%
Peginterferon Alpha2a
33%
Acute Hepatitis
33%
Medicine and Dentistry
Child
100%
Adolescent
100%
Patient
100%
Chronic Hepatitis C
100%
Hepatitis C Virus
30%
Adverse Event
20%
Growth
10%
Combination Therapy
10%
Fever
10%
Adult
10%
Treatment Response
10%
Virus RNA
10%
Genotype
10%
Drug Therapy
10%
Dermatitis
10%
Anemia
10%
Loss of Appetite
10%
Pediatrics Patient
10%
Abdominal Pain
10%
Irritability
10%
Neutropenia
10%
Acute Hepatitis
10%
Thyrotoxicosis
10%
Biochemistry, Genetics and Molecular Biology
Hepatitis C Virus
100%
Genotype
100%
Ribavirin
100%
Growth
25%
RNA Virus
25%
Height
25%
Pediatrics
25%
Genotyping
25%
Dose
25%
Interferon
25%
Mood
25%
Serology
25%
Irritability
25%
Nursing and Health Professions
Chronic Hepatitis C
100%
Peginterferon Alpha2a Plus Ribavirin
100%
Hepatitis C
30%
Ribavirin
30%
Adverse Event
20%
Combination Therapy
10%
Drug Therapy
10%
Depression
10%
Dose
10%
Height
10%
Fever
10%
Sustained Virologic Response
10%
Abdominal Pain
10%
Peginterferon Alpha2a
10%
Peginterferon Alpha
10%
Serology
10%
Loss of Appetite
10%
Treatment Response
10%
Dermatitis
10%
Acute Hepatitis
10%
Thyrotoxicosis
10%
Alpha2a Interferon
10%
Flu Like Syndrome
10%
Anemia
10%
Virus RNA
10%
Neutropenia
10%